Clinical trialRSSYesterday
Adding LAM-001 inhaled therapy leads to broad benefits for PH
Researchers tested a new inhaled medicine called LAM-001 on patients with two types of lung disease: pulmonary hypertension combined with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). All patients who finished the small early-stage trial showed significant improvement in their symptoms. The results are encouraging enough that the company plans to continue testing this medicine.
WHY IT MATTERSIf LAM-001 proves effective in larger trials, it could offer a new treatment option for PH-ILD patients, a condition with limited approved therapies that causes progressive breathing difficulty and high pressure in lung blood vessels.